Your session is about to expire
← Back to Search
Cabozantinib for Liver Cancer
Study Summary
This trial is testing a new combination cancer therapy to see if it is safe and effective for treating people with HCC.
- Liver Cancer
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2022 Phase 2 trial • 45 Patients • NCT02101736Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
What is the regulatory status of Cabozantinib?
"While there is some evidence to support the safety of Cabozantinib, it only received a score of 2 because Phase 2 trials have not shown any efficacy."
Has this clinical trial been done before?
"Medarex conducted the first study on cabozantinib in 2010 with 127 participants. The success of this trial led to Cabozantinib receiving Phase 1 drug approval. As of now, 830 trials are underway in 54 countries and 2596 cities worldwide."
Are participants still being enrolled in this experiment?
"No, this study is not recruiting patients at the moment. The listing on clinicaltrials.gov says that the last time this trial was updated was on July 10th, 2022. Even though this particular trial isn't enrolling individuals currently, there are 1686 other trials with open enrollment."
With what type of ailment is Cabozantinib regularly used?
"Cabozantinib has shown to be effective in treatment against malignant neoplasms, unresectable melanoma, and squamous cell carcinoma."
Are there other examples in which Cabozantinib has been used for research purposes?
"There are 830 ongoing studies investigating the efficacy of Cabozantinib. Out of these, 92 have reached Phase 3. The majority of trials are based in Basel, BE; however, there are 43914 total locations running clinical trials for this medication."
How many test subjects are needed for this research project?
"The last update to this study was on July 10th, 2022 and it is no longer recruiting patients. 856 other studies are currently looking for patients with liver carcinoma while 830 studies focus on Cabozantinib."
Share this study with friends
Copy Link
Messenger